William Blair Investment Management LLC Has $13.02 Million Stake in Quanterix Corporation $QTRX

William Blair Investment Management LLC grew its position in Quanterix Corporation (NASDAQ:QTRX) by 55.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,046,449 shares of the company’s stock after acquiring an additional 731,169 shares during the period. William Blair Investment Management LLC owned 4.38% of Quanterix worth $13,015,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC acquired a new stake in Quanterix during the 4th quarter valued at $26,000. Quarry LP boosted its stake in Quanterix by 277,300.0% in the third quarter. Quarry LP now owns 5,548 shares of the company’s stock worth $30,000 after purchasing an additional 5,546 shares in the last quarter. R Squared Ltd acquired a new position in Quanterix in the third quarter worth $64,000. HUB Investment Partners LLC bought a new stake in shares of Quanterix during the second quarter worth $81,000. Finally, Jain Global LLC bought a new stake in shares of Quanterix during the third quarter worth $94,000. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Stock Performance

NASDAQ QTRX opened at $2.69 on Tuesday. The stock has a market capitalization of $126.73 million, a P/E ratio of -1.14 and a beta of 1.15. Quanterix Corporation has a 52 week low of $2.39 and a 52 week high of $8.77. The stock has a fifty day moving average of $3.40 and a 200-day moving average of $5.36.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.12. The business had revenue of $35.90 million for the quarter, compared to analyst estimates of $36.84 million. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%. Equities research analysts forecast that Quanterix Corporation will post -0.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Canaccord Genuity Group cut their price target on Quanterix from $8.00 to $4.00 and set a “hold” rating for the company in a report on Monday, April 20th. Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen lowered their price objective on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $4.00.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.